Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC

Partner | Cancer Centers | <b>UCSD Moores Cancer Center </b>

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Kathryn Gold, MD, medical oncologist and professor of medicine at Moores Cancer Center at UC San Diego Health, discusses best practices with the use of sotorasib (Lumakras) in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC).

Despite the availability of sotorasib, chemotherapy and immunotherapy remain the standard frontline options for this patient population, according to Gold. Almost all of these patients should receive a form of immunotherapy, either alone or in combination with chemotherapy, as part of their frontline treatment, Gold says. The selection of immunotherapy should be based on a patient’s PD-L1 expression levels, Gold adds.

If a patient progresses with or without chemotherapy, sotorasib should be considered, Gold says. Several ongoing trials are examining combinations with sotorasib, including pairing the targeted agent with immunotherapy or chemotherapy, to improve response rates. Efforts are also being made to potentially move the agent earlier on in the treatment journey, Gold explains. It remains to be seen which subgroups of patients with NSCLC will benefit most from these approaches, but ongoing studies could potentially provide answers, Gold concludes.